Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 9/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA3 | P07451 | 2/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | CA6 | P23280 | 2/20 | 0.50 |
| ▸ | CA5A | P35218 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10788495 | 1.00 | DNM1 (0.50) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL10699102 | 1.00 | DNM1 (0.50) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL2003831 | 1.00 | DNM1 (0.50) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL2005160 | 1.00 | DNM1 (0.50) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL22584994 | 1.00 | DNM1 (0.50) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL2008237 | 0.97 | — | — | |
| SCHEMBL896776 | 0.87 | — | — | |
| SCHEMBL19713116 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL16628517 | 0.84 | — | — | |
| SCHEMBL4234450 | 0.83 | MGAM (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964738-B2 | Pharmaceutical compositions and methods of use of lipophilic, silicon-substituted, cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs and derivatives | SILAMED, INC. (US) | 2011-06-21 | — | — | US | claimed |
| US-20070129331-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF LIPOPHILIC, SILICON-SUBSTITUTED, CYCLOOXYGENASE-2 SELECTIVE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND DERIVATIVES | RND PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | US | claimed |
| EP-1737471-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF LIPOPHILIC, SILICON-SUBSTITUTED, CYCLOOXYGENASE-2 SELECTIVE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND DERIVATIVES | RND Pharmaceuticals (US) | 2007-01-03 | — | — | EP | claimed |
| WO-2005102358-A2 | SILICONE-SUBSTITUTED COX-2 SELECTIVE INHIBITORS | RND PHARMACEUTICALS (US) | 2005-11-03 | — | — | WO | claimed |
| US-20190304707-A1 | PHOTOELECTRIC CONVERSION ELEMENT, SOLAR CELL AND COMPOSITION | FUJIFILM CORPORATION (JP) | 2019-10-03 | — | — | US | disclosed |
| US-10418186-B2 | Photoelectric conversion element, solar cell and composition | FUJIFILM CORPORATION (JP) | 2019-09-17 | — | — | US | disclosed |
| US-20170330694-A1 | PHOTOELECTRIC CONVERSION ELEMENT, SOLAR CELL AND COMPOSITION | FUJIFILM CORPORATION (JP) | 2017-11-16 | — | — | US | disclosed |
| US-20170330694-A1 | PHOTOELECTRIC CONVERSION ELEMENT, SOLAR CELL AND COMPOSITION | FUJIFILM CORPORATION (JP) | 2017-11-16 | — | — | US | disclosed |
| US-7964738-B2 | Pharmaceutical compositions and methods of use of lipophilic, silicon-substituted, cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs and derivatives | SILAMED, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-20090306015-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HIGHLY LIPOPHILIC SULFHYDRYL COMPOUNDS | SILAMED, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090054369-A1 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS | RND PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| EP-1968609-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HIGHLY LIPOPHILIC SULFHYDRYL COMPOUNDS | RND Pharmaceuticals, Inc. (US) | 2008-09-17 | — | — | EP | disclosed |
| EP-1919929-A2 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS | RND Pharmaceuticals, Inc. (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007073560-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HIGHLY LIPOPHILIC SULFHYDRYL COMPOUNDS | RND PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | WO | disclosed |
| US-20070129331-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF LIPOPHILIC, SILICON-SUBSTITUTED, CYCLOOXYGENASE-2 SELECTIVE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND DERIVATIVES | RND PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | US | disclosed |
| WO-2007019221-A2 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS | RND PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| EP-1737471-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF LIPOPHILIC, SILICON-SUBSTITUTED, CYCLOOXYGENASE-2 SELECTIVE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND DERIVATIVES | RND Pharmaceuticals (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005102358-A2 | SILICONE-SUBSTITUTED COX-2 SELECTIVE INHIBITORS | RND PHARMACEUTICALS (US) | 2005-11-03 | — | — | WO | disclosed |
| US-4868189-A | ANTICANCER AGENTS | SANWA KAGAKU KENKYUSHO CO. (JP) | 1989-09-19 | — | — | US | disclosed |
| EP-0280841-A2 | Organo-silicone compounds and use thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1988-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054369-A1 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS | SI, SLC29A2, SLC29A1 | DNM1 4270/4885CA12 1114/4885CA1 217/4885 |
| US-20070129331-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF LIPOPHILIC, SILICON-SUBSTITUTED, CYCLOOXYGENASE-2 SELECTIVE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND DERIVATIVES | PTGES2, PTGS2, SI | DNM1 3934/4885CA12 149/4885CA1 39/4885 |
| US-20090306015-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HIGHLY LIPOPHILIC SULFHYDRYL COMPOUNDS | SI, SCLY, SGMS1 | DNM1 3737/4885CA12 942/4885CA1 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.